NEW YORK, Dec. 16, 2019 -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: ArQule, Inc. (NASDAQ: ARQL)The investigation.
NEW YORK, NY / ACCESSWIRE / December 21, 2019 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Care.com, Inc. (NYSE:CRCM) The investigation concerns ...
Acquisitions expected to match 2019 numbers, but buyers will likely seek less costly additions Continue reading...
Moore Kuehn, PLLC, a securities law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders:
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 10) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics ...
Merck (MRK) offers to acquire ArQule for a deal value of $2.7 billion. The transaction will add ArQule's lead investigational candidate ARQ 531 to Merck's oncology portfolio.
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of ArQule, Inc. ("ArQule" or the "Company") (NASDAQ: ARQL) in connection with the proposed acquisition of the Company by a subsidiary of Merck & Co., Inc. (NYSE: MRK). Under the terms of the acquisition agreement, ARQL shareholders will receive $20 per share in cash. The deal is scheduled to close in the first quarter of 2020.
increasing M&A deals and cutting edge therapies are driving biotech ETFs higher
Principia Biopharma stock has rocketed 32% this week amid enthusiasm for its technology, BTK inhibition — highlighted by notable moves from pharmaceutical giants Merck and Sanofi.
WILMINGTON, Del., Dec. 28, 2019 -- Rigrodsky & Long, P.A. announces that it is investigating: Synthorx, Inc. (NASDAQ GS: THOR) regarding possible breaches of fiduciary.
NEW YORK, NY / ACCESSWIRE / December 11, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New ...
BALA CYNWYD, PA / ACCESSWIRE / December 17, 2019 / Brodsky & Smith, LLC reminds investors of investigations it is conducting regarding the following companies for possible breaches of fiduciary duty and ...
BALA CYNWYD, PA / ACCESSWIRE / December 30, 2019 / Brodsky & Smith, LLC reminds investors of investigations it is conducting regarding the following companies for possible breaches of fiduciary duty and ...
WILMINGTON, Del., Dec. 23, 2019 -- Rigrodsky & Long, P.A. announces that it is investigating: LogMeIn, Inc. (NASDAQ GS: LOGM) regarding possible breaches of fiduciary.
It has been a fantastic year for equity investors as Donald Trump pressured Federal Reserve to reduce interest rates and finalized the first leg of a trade deal with China. If you were a passive index fund investor, you had seen gains of 31% in your equity portfolio in 2019. However, if you were an […]
NEW YORK, NY / ACCESSWIRE / December 24, 2019 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Synthorx , Inc. (NASDAQ:THOR) The investigation concerns ...
Following the new deals in the healthcare space, a few biotech ETFs hit new highs.
BALA CYNWYD, PA / ACCESSWIRE / December 10, 2019 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of ArQule, Inc. ("ArQule" ...
Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating ArQule, Inc ("ArQule" or the "Company") (Nasdaq: ARQL) relating to the sale of the Company to Merck Sharp & Dohme Corp. Under the terms of the Merger, ArQule shareholders will have the right to receive $20.00 in cash for each share of ArQule common stock owned.
WILMINGTON, Del., Dec. 12, 2019 -- Rigrodsky & Long, P.A. announces that it is investigating: Progenics Pharmaceuticals, Inc. (NASDAQ GS: PGNX) regarding possible.